546 related articles for article (PubMed ID: 26303828)
1. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
6. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
Fabi A; Alesini D; Valle E; Moscetti L; Caputo R; Caruso M; Carbognin L; Ciccarese M; La Verde N; Arpino G; Cannita K; Paris I; Santini D; Montemurro F; Russillo M; Ferretti G; Filippelli G; Rossello R; Fabbri A; Zambelli A; Leonardi V; D'Ottavio AM; Nisticò C; Stani S; Giampaglia M; Scandurra G; Catania G; Malaguti P; Giannarelli D; Cognetti F
Breast; 2018 Oct; 41():137-143. PubMed ID: 30092500
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
8. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
9. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
[TBL] [Abstract][Full Text] [Related]
10. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
16. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
[TBL] [Abstract][Full Text] [Related]
19. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
Michel LL; Bermejo JL; Gondos A; Marmé F; Schneeweiss A
Anticancer Res; 2015 Sep; 35(9):5085-90. PubMed ID: 26254411
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
